ARTICLE | Company News
Amorfix, University of Toronto deal
February 6, 2006 8:00 AM UTC
The university granted Amorfix an exclusive worldwide license to targets on superoxide dismutase-1 ( SOD1), which the company plans to use in developing a treatment for amyotrophic lateral sclerosis (...